Literature DB >> 16723803

AT1 receptor antagonist restores cardiac ryanodine receptor function, rendering isoproterenol-induced failing heart less susceptible to Ca2+ -leak induced by oxidative stress.

Takahiro Tokuhisa1, Masafumi Yano, Masakazu Obayashi, Toshiyuki Noma, Mamoru Mochizuki, Tetsuro Oda, Shinichi Okuda, Masahiro Doi, Jinyao Liu, Yasuhiro Ikeda, Takeshi Yamamoto, Tomoko Ohkusa, Masunori Matsuzaki.   

Abstract

BACKGROUND: The Ca(2+) regulatory proteins in the sarcoplasmic reticulum (SR) play a key role in the pathogenesis of heart failure. In the present study the effect of chronic beta-receptor-stimulation on cardiac and SR functions was assessed, with or without angiotensin-II receptor antagonist treatment recently reported to have anti-beta-adrenergic activity. METHODS AND
RESULTS: Rats were treated with isoproterenol with (+) or without (-) candesartan (CAN) and then SR vesicles were isolated from the left ventricular muscle. Both Ca(2+)-uptake and the amount of SR Ca(2+)-ATPase were significantly lower in the CAN (-) group than in the shams, but those were almost normally restored in the CAN (+). Although the level of the protein kinase A (PKA)-phosphorylation of the SR Ca(2+) release channel, known as the ryanodine receptor (RyR2), was elevated in the CAN (-), no Ca(2+)-leak was detected. However, SIN-1 (O(2) (-) donor) induced Ca(2+)-leak in the CAN (-) at a 10-fold lower dose than in the sham and CAN (+). In cardiomyocytes, SIN-1 decreased cell shortening and the peak Ca(2+) transient and prolonged time from peak to 70% decline in CAN (-), again at 10-fold lower dose than in the sham and CAN (+).
CONCLUSION: Chronic beta-receptor-stimulation did not induce any Ca(2+)-leak from the SR, whereas Ca(2+)-leak was easily induced when oxidative stress was applied to the PKA-phosphorylated RyR2. Candesartan not only improved Ca(2+)-uptake, but also prevented PKA-phosphorylation, rendering the SR less susceptible to Ca(2+)-leak.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723803     DOI: 10.1253/circj.70.777

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  7 in total

1.  Direct comparison of cervical and high thoracic spinal cord injury reveals distinct autonomic and cardiovascular consequences.

Authors:  Heidi L Lujan; Stephen E DiCarlo
Journal:  J Appl Physiol (1985)       Date:  2020-01-30

2.  Inhibition of renin-angiotensin system (RAS) reduces ventricular tachycardia risk by altering connexin43.

Authors:  Shahriar Iravanian; Ali A Sovari; Harvey A Lardin; Hong Liu; Hong D Xiao; Elena Dolmatova; Zhe Jiao; Brett S Harris; Emily A Witham; Robert G Gourdie; Heather S Duffy; Kenneth E Bernstein; Samuel C Dudley
Journal:  J Mol Med (Berl)       Date:  2011-05-07       Impact factor: 4.599

Review 3.  Ryanodine receptor-mediated arrhythmias and sudden cardiac death.

Authors:  Lynda M Blayney; F Anthony Lai
Journal:  Pharmacol Ther       Date:  2009-04-01       Impact factor: 12.310

4.  Effects of therapy using the Celacade system on structural and functional cardiac remodelling in rats following myocardial infarction.

Authors:  Mei Luo Zhang; Jie Mei; Lori Anne Archer; Masakazu Obayashi; Ni Diao; Bruno Stuyvers; Henk E D J ter Keurs
Journal:  Can J Cardiol       Date:  2009-07       Impact factor: 5.223

5.  Chronic, complete cervical6-7 cord transection: distinct autonomic and cardiac deficits.

Authors:  Heidi L Lujan; Anne Tonson; Robert W Wiseman; Stephen E DiCarlo
Journal:  J Appl Physiol (1985)       Date:  2018-02-22

Review 6.  Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter?

Authors:  Pietro Francia; Francesca Palano; Giuliano Tocci; Carmen Adduci; Agnese Ricotta; Lorenzo Semprini; Massimo Caprinozzi; Cristina Balla; Massimo Volpe
Journal:  ISRN Cardiol       Date:  2014-02-06

Review 7.  Involvement of Oxidative Stress in the Development of Subcellular Defects and Heart Disease.

Authors:  Naranjan S Dhalla; Vijayan Elimban; Monika Bartekova; Adriana Adameova
Journal:  Biomedicines       Date:  2022-02-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.